Cargando…
Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
BACKGROUND: Myocarditis is a rare but life-threatening adverse event of cancer treatments with immune checkpoint inhibitors (ICIs). Recent guidelines recommend the use of high doses of corticosteroids as a first-line treatment, followed by intensified immunosuppressive therapy (IIST) in the case of...
Autores principales: | Cautela, Jennifer, Zeriouh, Sarah, Gaubert, Melanie, Bonello, Laurent, Laine, Marc, Peyrol, Michael, Paganelli, Franck, Lalevee, Nathalie, Barlesi, Fabrice, Thuny, Franck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7725077/ https://www.ncbi.nlm.nih.gov/pubmed/33298621 http://dx.doi.org/10.1136/jitc-2020-001887 |
Ejemplares similares
-
Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020) -
Diagnostic Value of the International Society of Cardio‐Oncology Definition for Suspected Immune Checkpoint Inhibitor–Associated Myocarditis
por: Deharo, Francois, et al.
Publicado: (2023) -
Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021) -
Wearable cardioverter defibrillator: Bridge or alternative to implantation?
por: Barraud, Jeremie, et al.
Publicado: (2017) -
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?
por: Thuny, Franck, et al.
Publicado: (2022)